Ionis Pharmaceuticals, Inc. Current Assets
Ionis Pharmaceuticals, Inc. (IONS) had Current Assets of $2.49 billion as of 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Balance Sheet › Assets › Assets, Current
us-gaap:AssetsCurrent · last filed 2026-07-29
- 2026-06-30: Assets, Current $2.49B.
- 2026-03-31: Assets, Current $2.94B.
- 2025-12-31: Assets, Current $2.99B.
- 2025-09-30: Assets, Current $2.52B.
| Period end | Assets, Current | Assets, Current as first filed |
|---|---|---|
| 2026-06-30 | $2.49B 10-Q · filed 2026-07-29 | |
| 2026-03-31 | $2.94B 10-Q · filed 2026-04-29 | |
| 2025-12-31 | $2.99B 10-Q · filed 2026-07-29 | |
| 2025-09-30 | $2.52B 10-Q · filed 2025-10-29 | |
| 2025-06-30 | $2.58B 10-Q · filed 2025-07-30 | |
| 2025-03-31 | $2.42B 10-Q · filed 2025-04-30 | |
| 2024-12-31 | $2.62B 10-K · filed 2026-02-26 | |
| 2024-09-30 | $2.71B 10-Q · filed 2024-11-06 | |
| 2024-06-30 | $2.33B 10-Q · filed 2024-08-01 | |
| 2024-03-31 | $2.42B 10-Q · filed 2024-05-07 | |
| 2023-12-31 | $2.64B 10-K · filed 2025-02-19 | |
| 2023-09-30 | $2.58B 10-Q · filed 2023-11-02 | |
| 2023-06-30 | $2.62B 10-Q · filed 2023-08-09 | |
| 2023-03-31 | $2.54B 10-Q · filed 2023-05-03 | |
| 2022-12-31 | $2.20B 10-K · filed 2024-02-21 | |
| 2022-09-30 | $2.15B 10-Q · filed 2022-11-09 | |
| 2022-06-30 | $2.19B 10-Q · filed 2022-08-09 | |
| 2022-03-31 | $2.25B 10-Q · filed 2022-05-04 | |
| 2021-12-31 | $2.35B 10-K · filed 2023-02-22 | |
| 2021-09-30 | $2.16B 10-Q · filed 2021-11-03 | |
| 2021-06-30 | $2.24B 10-Q · filed 2021-08-04 | |
| 2021-03-31 | $1.99B 10-Q · filed 2021-05-05 | |
| 2020-12-31 | $2.13B 10-K · filed 2022-02-25 | |
| 2020-09-30 | $2.54B 10-Q · filed 2020-11-04 | |
| 2020-06-30 | $2.53B 10-Q · filed 2020-08-05 | |
| 2020-03-31 | $2.56B 10-Q · filed 2020-05-06 | |
| 2019-12-31 | $2.72B 10-K · filed 2021-02-24 | |
| 2019-09-30 | $2.41B 10-Q · filed 2019-11-06 | |
| 2019-06-30 | $2.41B 10-Q · filed 2019-08-08 | |
| 2019-03-31 | $2.37B 10-Q · filed 2019-05-09 | |
| 2018-12-31 | $2.21B 10-K · filed 2020-03-02 | |
| 2018-09-30 | $2.08B 10-Q · filed 2018-11-06 | |
| 2018-06-30 | $2.08B 10-Q · filed 2018-08-07 | |
| 2018-03-31 | $1.14B 10-Q · filed 2018-05-07 | |
| 2017-12-31 | $1.17B 10-K · filed 2019-03-01 | $1.17B 10-K · filed 2018-02-28 |
| 2017-09-30 | $1.11B 10-Q · filed 2017-11-07 | |
| 2017-06-30 | $964.36M 10-Q · filed 2017-08-09 | |
| 2017-03-31 | $962.37M 10-Q · filed 2017-05-09 | |
| 2016-12-31 | $797.93M 10-K · filed 2018-02-28 | |
| 2016-09-30 | $730.33M 10-Q · filed 2016-11-09 | |
| 2016-06-30 | $697.97M 10-Q · filed 2016-08-09 | |
| 2016-03-31 | $763.91M 10-Q · filed 2016-05-05 | |
| 2015-12-31 | $837.00M 10-K · filed 2017-03-01 | |
| 2015-09-30 | $868.26M 10-Q · filed 2015-11-09 | |
| 2015-06-30 | $855.45M 10-Q · filed 2015-08-05 | |
| 2015-03-31 | $835.43M 10-Q · filed 2015-05-05 | |
| 2014-12-31 | $836.60M 10-K · filed 2016-02-26 | |
| 2014-09-30 | $681.16M 10-Q · filed 2014-11-07 | |
| 2014-06-30 | $705.80M 10-Q · filed 2014-08-04 | |
| 2014-03-31 | $722.05M 10-Q · filed 2014-05-06 | |
| 2013-12-31 | $735.51M 10-K · filed 2015-03-02 | |
| 2013-09-30 | $763.30M 10-Q · filed 2013-11-05 | |
| 2013-06-30 | $669.06M 10-Q · filed 2013-08-06 | |
| 2013-03-31 | $431.83M 10-Q · filed 2013-05-07 | |
| 2012-12-31 | $423.44M 10-K · filed 2014-03-03 | |
| 2012-09-30 | $361.59M 10-Q · filed 2012-11-06 | |
| 2012-06-30 | $350.42M 10-Q · filed 2012-08-06 | |
| 2012-03-31 | $347.61M 10-Q · filed 2012-05-09 | |
| 2011-12-31 | $360.14M 10-K · filed 2013-02-28 | |
| 2011-09-30 | $377.09M 10-Q · filed 2011-11-08 | |
| 2011-06-30 | $410.72M 10-Q · filed 2011-08-08 | |
| 2011-03-31 | $437.39M 10-Q · filed 2011-05-06 | |
| 2010-12-31 | $483.14M 10-K · filed 2012-02-29 | |
| 2010-09-30 | $507.55M 10-Q · filed 2010-11-05 | |
| 2010-06-30 | $536.88M 10-Q · filed 2010-08-09 | |
| 2009-12-31 | $596.13M 10-K · filed 2011-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |